Investment report on Spectrum Pharmaceuticals from BeaconEquity.com

BeaconEquity.com announces an investment report featuring biotech company Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/SPPI

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

Spectrum Pharmaceuticals Inc. (SPPI) is a commercial stage biopharmaceutical company engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. On December 15, 2008, Spectrum and Cell Therapeutics Inc. (CTI) partnered to form a joint venture, RIT Oncology LLC (RIT), to develop ZEVALIN ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Ltd., Spectrum Pharmaceuticals GmbH, RIT Oncology LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.  

Message Board Search for SPPI: http://www.boardcentral.com/boards/SPPI

In the report, the analyst notes:

"Consolidated revenue of $8.6 million was comprised of product sales of $5.2 million - $5.1 million from ZEVALIN, an increase of 8.5% over third quarter 2009, and $0.1 million from FUSILEV - $1.5 million attributable to the milestone payment upon full enrollment of the apaziquone phase 3 trials, and $1.9 million attributable to the amortization of the Allergan licensing fee.

"SPPI recently announced that the first patient has been dosed in a National Cancer Institute (NCI)-sponsored phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies. The trial is designed to determine what drug doses can be safely administered together in patients, and to make dose recommendations for future clinical trials."